Sulfasalazine
- Generic Name
- Sulfasalazine
- Brand Names
- Azulfidine, Salazopyrin, Salazopyrin En-tabs
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14N4O5S
- CAS Number
- 599-79-1
- Unique Ingredient Identifier
- 3XC8GUZ6CB
- Background
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry ...
- Indication
In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis. Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pedi...
- Associated Conditions
- Crohn's Disease (CD), Distal Ulcerative Colitis, Mild to Moderate Ulcerative Colitis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Ulcerative Colitis in Remission
- Associated Therapies
- -
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 87
- Registration Number
- NCT01198145
- Locations
- 🇺🇸
Boulder Community Hospital, Boulder, Colorado, United States
🇺🇸Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
🇺🇸St. Joseph Hospital, Denver, Colorado, United States
Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- P. Verschueren
- Target Recruit Count
- 400
- Registration Number
- NCT01172639
- Locations
- 🇧🇪
Reuma instituut Hasselt, Hasselt, Belgium
🇧🇪ZNA Jan Palfijn, Merksem, Belgium
🇧🇪Henri Serruys ziekenhuis, Oostende, Belgium
Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis
- Conditions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 80
- Registration Number
- NCT00889694
Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)
- Conditions
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 80
- Registration Number
- NCT00844142
- Locations
- 🇩🇪
Charité Campus Mitte, Rheumatology, Berlin, Germany
🇩🇪Praxis Mielke, Berlin, Germany
🇩🇪Waldkrankenhaus, Berlin, Germany
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT00637780
- Locations
- 🇲🇽
Private Office, Guadalajara, Jalisco, Mexico
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
Sulfasalazine and Endothelial Function
- Conditions
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- Boston University
- Target Recruit Count
- 60
- Registration Number
- NCT00554203
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 353
- Registration Number
- NCT00405275
- Locations
- 🇺🇸
VA Medical Center, Loma Linda, Loma Linda, California, United States
🇺🇸VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States
🇺🇸Geisinger Medical Group - State College, State College, Pennsylvania, United States
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
- Conditions
- Interventions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 755
- Registration Number
- NCT00259610
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.